Gyre Therapeutics (GYRE) to Release Quarterly Earnings on Thursday

Posted by Brian Himes on May 7th, 2025

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $28.40 million for the quarter.

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The company had revenue of $27.87 million for the quarter, compared to analysts’ expectations of $23.50 million.

Gyre Therapeutics Stock Down 1.0 %

Shares of NASDAQ:GYRE opened at $8.72 on Wednesday. The company has a market capitalization of $817.44 million, a P/E ratio of 174.40 and a beta of 1.90. The stock’s fifty day simple moving average is $9.17 and its 200-day simple moving average is $11.07. Gyre Therapeutics has a 52-week low of $6.11 and a 52-week high of $19.00.

Analyst Ratings Changes

Separately, Noble Financial assumed coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They set an “outperform” rating on the stock.

Read Our Latest Research Report on Gyre Therapeutics

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Gyre Therapeutics stock. Bank of America Corp DE increased its holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) by 40.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,937 shares of the company’s stock after purchasing an additional 1,996 shares during the period. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 as of its most recent SEC filing. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.